USC researchers find new clues to risk of Hodgkin lymphomaApril 02, 2008Unique study of twins offers new hypothesis on why disease affects some, and not others A long-term study of twins has led University of Southern California (USC) researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein (interleukin-12). "We found that lower levels of the protein interleukin-12, involved in fighting intracellular infections, increases susceptibility to young adult Hodgkin lymphoma," says Wendy Cozen, D.O., M.P.H, associate professor of preventive medicine at the Keck School of Medicine of USC. " Cozen is lead author on the study entitled, "Interleukin-2, interleukin-12, and interferon-¦Ã levels and risk of young adult Hodgkin lymphoma," published in the April 1 issue of the journal, Blood.
The study is accompanied by an editorial entitled "Hodgkin twins: double good, double trouble," by Richard F. Ambinder of the Johns Hopkins School of Medicine. The work is based on patient populations found in the International Twin Study and California Twin Program, unique registries of twin pairs developed and maintained in the Department of Preventive Medicine at USC. Hodgkin lymphoma is the most common type of cancer among young women and the second most common type among young men. But while the 5-year survival rate is high compared to that of other cancers, the treatment may cause complications later in life. According to Cozen, this study, along with a previous one her group published in 2007, provides the first clear evidence that individual differences in immune response (via cytokine secretion) may lead to the development of Hodgkin lymphoma. "We previously showed that there is a substantial genetic risk for adolescent and young adult Hodgkin lymphoma, and that another immune response protein (interleukin-6) was related to risk," says Cozen. "We are pursuing the hypothesis that variations in genes control the secretion of these immune response proteins (cytokines) predicting Hodgkin lymphoma risk." Eventually, based on the group's current work, researchers may be able to develop novel treatments to correct the abnormal immune response thereby offering alternatives to current therapy. Cozen and her group are conducting an expanded study among adolescent and young adult Hodgkin lymphoma patients and their parents in Los Angeles. The group is studying these genes and others that control the immune response in hopes of confirming their previous results and to further define the inherited patterns that explain the genetic part of the risk. Cozen adds that colleagues from the National Cancer Institute and Washington University in St. Louis, will also be studying early exposures to infectious agents such as bacteria and viruses, which may interact with the immune system leading to Hodgkin lymphoma. University of Southern California Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Diarrhea Cancer Therapy Cell Phone Epithelial Cells Hepatitis Genetics Contraception Oral Cancer Hydrogen Cell Death Liver Cells Leukaemia Bird Species Search Engine Water Language Insecticide Large Hadron Collider Cardiovascular Risk Reproduction Eye Cancer Drug Discovery Bees Gamma-ray Glucose Levels
See More: Science News Tags | |||||||||||||||||||||
|
Related Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News Articles Anti-inflammatory drugs may defeat a treatment-resistant type of cancer Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease. Two targeted therapies likely better than one in patients with aggressive lymphoma When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG). Do patients at risk for B-cell malignancy need antiviral treatment? Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists. However the precise mechanism remains unclear. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. New therapy prevents dangerous side effect for lymphoma patients Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology. Novel treatments show improvements in survival and response rates for leukemia and lymphoma The use of dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the most common type of childhood cancer, may help reduce the risk of relapse. Novel therapeutic approaches may improve patient outcomes in several platelet disorders Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood. Hodgkin lymphoma -- new characteristics discovered Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern. New ovarian stimulation technique offers more cancer patients the chance to preserve their fertility Researchers have shown for the first time that it is possible to stimulate a woman's ovaries to produce eggs for collection during the final phase of the menstrual cycle. Adding epratuzumab to standard therapy Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma. More Hodgkin Lymphoma Current Events and Hodgkin Lymphoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||